共 50 条
- [22] Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors[J]. DRUG SAFETY, 2018, 41 (04) : 357 - 361Verden, AbrilDimbil, MoKyle, RobertOverstreet, BrianHoffman, Keith B.
- [23] Medical Devices and the FDA Approval Process Balancing Safety and Innovation[J]. ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (20) : 1831 - 1833Redberg, Rita F.
- [24] US FDA's safety monitoring of drugs with expedited approval[J]. LANCET ONCOLOGY, 2016, 17 (03): : 281 - 281Furlow, Bryant
- [25] FDA amends postmarket program for medical devices[J]. JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (01) : 24N - 24N不详
- [26] Dangers of rosuvastatin identified before and after FDA approval[J]. LANCET, 2004, 363 (9427): : 2189 - 2190Wolfe, SM
- [27] Withdrawing FDA Approval of Midodrine After Marketing Reply[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (08): : 782 - 782Dhruva, Sanket S.Redberg, Rita F.
- [28] Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors[J]. Drug Safety, 2018, 41 : 357 - 361Abril VerdenMo DimbilRobert KyleBrian OverstreetKeith B. Hoffman
- [29] FDA leadership picks may stress safety over swift approval[J]. Nature Medicine, 2009, 15 : 466 - 466Kirsten Dorans
- [30] FDA leadership picks may stress safety over swift approval[J]. NATURE MEDICINE, 2009, 15 (05) : 466 - 466Dorans, Kirsten
